Wize Pharma

Wize Pharma EBIT per Share

Delisted·Jan 10, 2019

The EBIT per Share of Wize Pharma (WIZP) as of Oct 6, 2026 is -0.07 USD. In the previous year, EBIT per Share was -0.20 USD — a change of -62.70% (higher).

EBIT per Share

-0.07USD

YoY

-62.70%

Last updated:

EBIT per Share of Wize Pharma is 2026 -0.07 USD. EBIT per Share of Wize Pharma was 2025 -0.20 USD. It decreases by -62.70% higher compared to the previous year.

The Wize Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
-0.41 USD
Jan 1, 2018
-0.41 USD
Jan 1, 2019
-0.20 USD
Jan 1, 2020
-0.07 USD
Jan 1, 2021 (e)
0.00 USD
Jan 1, 2022 (e)
0.00 USD
Jan 1, 2023 (e)
0.00 USD
Jan 1, 2024 (e)
0.00 USD
The Wize Pharma EBIT per Share history
YEAREBIT per ShareYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD-100.00%
-0.07USD-62.70%
-0.20USD-50.72%
-0.41USD-1.78%
-0.41USD-71.23%
-1.43USD-73.24%
-5.36USD-117.51%
30.60USD-511.80%
-7.43USD+30.28%
-5.70USD+486.75%
-0.97USD+969.44%
-0.09USD-50.00%
-0.18USD0.00%
-0.18USD+100.00%
-0.09USD-200.00%
0.09USD—
Access this data via the Eulerpool API
Get Free API Key

Wize Pharma Stock analysis

What does Wize Pharma do? Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Wize Pharma stock

EBIT per Share of Wize Pharma is -0.07 USD in 2026.

EBIT per Share of Wize Pharma changed from -0.20 USD to -0.07 USD, representing a -62.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Wize Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Wize Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Wize Pharma